Cero Therapeutics Holdings, Inc.
CERO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001870404
No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCEROW
Key figures
- Market capNo recent closing price
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$19.9M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 20.2K
- Shares sold short
- Change
- +19.2K
- +1,911.5% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding CERO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CERO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Cero Therapeutics Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 13, 2024 (view filing)6:41 PM ET | Dec 11-13 | 2 days | YK Bioventures Opportunities GP I, LLC and 3 others10% Owner | SSale | −5.96M | $0.0672 | −$400.5K | −31.4%13.0M after | 3 lots |
| Dec 10, 2024 (view filing)8:44 PM ET | Dec 6-10 | 4 days | YK Bioventures Opportunities GP I, LLC and 3 others10% Owner | SSale | −3.66M | $0.1048 | −$383.4K | −16.2%19.0M after | 3 lots |
| Nov 20, 2024 (view filing)4:04 PM ET | Sep 25 | 56 daysLate | Sloan Stuart M10% Owner | SSaleCommon Stock, $0.0001 par value per share | −532.5K | $0.1043 | −$55.5K | −2.5%21.1M after | |
| Nov 14, 2024 (view filing)8:14 PM ET | Oct 10 | 35 daysLate | YK Bioventures Opportunities GP I, LLC and 3 others10% Owner | SSale | −3.25M | $0.10 | −$325.0K | −12.6%22.6M after |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in Cero Therapeutics Holdings, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding CERO in 13F filings for Q2 2026.
Holders of 5% or more of CERO
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Cero Therapeutics Holdings, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Atwood Brian G | 13D/A | 9.90%511.8K shares | +3.20 ppfrom 6.70% | Oct 30, 20243 filings | Apr 4, 2025 | SEC |